印刷

診療科・部門紹介
診療科・部門紹介

肝・胆・膵内科

肝・胆・膵内科

最終更新日 : 2023年7月20日

診療科の特徴｜診療実績｜スタッフ紹介｜トピックス｜治験・臨床試験｜業績｜専門研修のご案内

研究業績・論文発表

2018年

（筆頭著者）

  1. Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, Okusaka T, Furuse J.
    A phase II study of modified FOLFIRINOX for chemotherapy-na?ve patients with metastatic pancreatic cancer.
    Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023
  2. Sasaki T, Kanata R, Sasahira N.
    Needle fracture during endoscopic ultrasound-guided fine needle aspiration using a needle with a side hole.
    Endosc Int Open. 2018 May;6(5):E553-E557
  3. Sasaki T, Yoshio T, Fujisaki J.
    Adjusting the length and direction of the redundant duodenal stent using a detachable snare and endoclips.
    Dig Endosc. 2018 Sep;30(5):686-687
  4. Sasaki T, Yamada I, Matsuyama M, Sasahira N.
    Enteral stent placement for malignant afferent loop obstruction by the through-the-scope technique using a short-type single-balloon enteroscope.
    Endosc Int Open. 2018 Jul;6(7):E806-E811

（共同著者）

  1. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol. 2018 Feb;53(2):281-290
  2. Nakai Y, Yamamoto R, Matsuyama M, Sakai Y, Takayama Y, Ushio J, Ito Y, Kitamura K, Ryozawa S, Imamura T, Tsuchida K, Hayama J, Itoi T, Kawaguchi Y, Yoshida Y, Sugimori K, Shimura K, Mizuide M, Iwai T, Nishikawa K, Yagioka H, Nagahama M, Toda N, Saito T, Yasuda I, Hirano K, Togawa O, Nakamura K, Maetani I, Sasahira N, Isayama H. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD Hilar study. J Gastroenterol Hepatol. 2018 May;33(5):1146-1153
  3. Todaka A, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Nakamori S, Yachi Y, Henmi T, Kobayashi M, Boku N, Mori K, Fukutomi A. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas. 2018 May/Jun;47(5):631-636
  4. Nakachi K, Konishi M, Ikeda M, Shimada K, Okusaka T, Saiura A, Ishii H, Sugiyama M, Furuse J, Sakamoto H, Shimamura T, Ohta T. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol. 2018 Oct;23(5):894-899
  5. Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Morizane C, Mizuno N, Ikeda M, Ueno M, Furuse J. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci. 2018 Aug;109(8):2549-2557
  6. Nakatochi M, Lin Y, Ito H, Hara K, Kinoshita F, Kobayashi Y, Ishii H, Ozaka M, Sasaki T, Sasahira N, Morimoto M, Kobayashi S, Ueno M, Ohkawa S, Egawa N, Kuruma S, Mori M, Nakao H, Wang C, Nishiyama T, Kawaguchi T, Takahashi M, Matsuda F, Kikuchi S, Matsuo K. Prediction model for pancreatic cancer risk in the general Japanese population. PLoS One. 2018;13(9):e0203386.
  7. Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Oyama H, Kanai S, Suzuki T, Sato T, Hakuta R, Ishigaki K, Takeda T, Saito T, Mizuno S, Kogure H, Tada M, Koike K. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. Invest New Drugs. 2018 Dec;36(6):1093-1102
  8. Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer. 2018 Nov 21;106:78-88

2019年

（筆頭著者）

  1. Sasaki T, Kanata R, Yamada I, Matsuyama M, Ozaka M, Sasahira N.
    Improvement of treatment outcomes for metastatic pancreatic cancer: A real-world data analysis.
    In Vivo. 2019 Jan-Feb;33(1):271-276
  2. Sasaki T, Sato T, Nakai Y, Sasahira N, Isayama H, Koike K.
    Brain metastasis in pancreatic cancer: Two case reports.
    Medicine (Baltimore). 2019 Jan; 98(4): e14227.

（共同著者）

  1. Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I.
    TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Eur J Cancer. 2019 Jan,106:78-88
  2. Kuwai T, Yamaguchi T, Imagawa H, Yoshida S, Isayama H, Matsuzawa T, Yamada T, Saito S, Shimada M, Hirata N, Sasaki T, Koizumi K, Maetani I, Saida Y.
    Factors related to difficult self-expandable metallic stent placement for malignant colonic obstruction: A post hoc analysis of a multicenter study across Japan.
    Dig Endosc. 2019 Jan;31(1):51-58
  3. Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.
    A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Invest New Drugs. 2019 Apr;37(2):338-344
  4. Shirasu H, Todaka A, Omae K, Fujii H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Kobayashi M, Fukutomi A.
    The impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
    Cancer Sci. 2019 Feb;110(2):707-716
  5. Takeda T, Nakai Y, Mizuno S, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Watanabe T, Takahara N, Mouri D, Kogure H, Ito Y, Hirano K, Tada M, Isayama H, Koike K.
    Fluid sequestration is a useful parameter in the early identification of severe disease of acute pancreatitis.
    J Gastroenterol. 2019 Apr;54(4):359-366
  6. Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi M, Todaka A, Fukutomi A.
    FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Pancreatology. 2019 Mar;19(2):296-301
  7. Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.
    Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately.
    Ann Surg Oncol. 2019 May;26(5):1385-1393
  8. Kobayashi S, Ueno M, Omae K, Kuramochi H, Terao M, Mizuno N, Ozaka M, Ueno H, Uesugi K, Kobayashi N, Kobayashi M, Todaka A, Fukutomi A.
    Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer.
    Oncotarget. 2019;10(19):1775-1784
  9. Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group.
    Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.
    Gastric Cancer. 2020 Jan;23(1):118-125
  10. Saito T, Nakai Y, Mizuno S, Isayama H, Sasahira N, Watanabe T, Matsubara S, Arizumi T, Togawa O, Hirano K, Tsujino T, Ishigaki K, Hakuta R, Saito K, Takahara N, Hamada T, Kogure H, Tada M, Koike K.
    A randomized-controlled trial of early endotherapy versus wait-and-see policy for mild symptomatic pancreatic stones in chronic pancreatitis.
    Eur J Gastroenterol Hepatol. 2019 Aug;31(8):979-984
  11. Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Sato T, Hakuta R, Ishigaki K, Saito T, Hamada T, Mizuno S, Kogure H, Tada M, Koike K.
    A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
    J Chemother. 2019 Sep;31(5):284-289
  12. Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.
    Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study.
    Cancers (Basel). 2019 Jul 31;11(8)
  13. Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Ohkubo S, Nishida Ｔ.
    Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Eur J Cancer. 2019 Nov;121:29-39
  14. Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).
    Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Ann Oncol. 2019 Dec 1;30(12):1950-1958

2020年

（筆頭著者）

  1. Sasaki T, Ishibashi R, Yoshida S, Fujisawa T, Shinagawa H, Gon C, Nakai Y, Sasahira N, Saida Y, Isayama H.
    Comparing the mechanical properties of a self-expandable metallic stent for colorectal obstruction: a proposed measurement method of axial force using a new measurement machine.
    J Hepatobiliary Pancreat Sci. 2020 Sep;27(9):663-664
  2. Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, Sasaki T, Ozaka M, Sasahira N.
    Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
    BMC Cancer. 2020 May 20;20(1):449
  3. Sasaki T, Mie T, Takeda T, Nakagawa S, Ono Y, Takahashi Y, Sasahira N.
    Percutaneous insertion of a jejunal tube via the collapsed blind end of elevated jejunum by a balloon puncturing method assisted by a balloon enteroscope.
    J Hepatobiliary Pancreat Sci. 2020 Sep;27(9):663-664
  4. Takeda T, Sasaki T, Inoue Y, Mie T, Furukawa T, Kanata R, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Saiura A, Sasahira N.
    Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor location.
    Pancreatology. 2020 Sep;20(6):1123-1130
  5. Sasaki T, Takeda T, Sasahira N.
    Double stenting with EUS-CDS using a new anti-reflux metal stent for combined malignant biliary and duodenal obstruction.
    J Hepatobiliary Pancreat Sci. 2020 Nov;27(11):e15-e16
  6. Fukuda K, Sasaki T, Hirasawa T, Matsueda K, Nakao E, Mie T, Furukawa T, Yamada Y, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    A case of percutaneous transhepatic portal vein stent placement and endoscopic injection sclerotherapy for duodenal variceal rupture occurring during chemotherapy for unresectable perihilar cholangiocarcinoma.
    Clin J Gastroenterol. 2020 Dec;13(6):1150-1156
  7. Mie T, Sasaki T, Kanata R, Furukawa T, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Diagnostic yield of endoscopic ultrasound-guided tissue acquisition for small solid pancreatic lesions.
    Endosc Int Open. 2020 Oct;8(10):E1359-E1364
  8. Takeda T, Sasaki T, Mie T, Furukawa T, Kanata R, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer.
    Endosc Int Open. 2020 Nov;8(11):E1603-E1610

（共同著者）

  1. Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group.
    Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.
    Gastric Cancer. 2020 Jan;23(1):118-125
  2. Kobayashi S, Ueno M, Ikeda M, Ozaka M, Sano Y, Hirotani A, Tozuka Y, Fukushima T, Tezuka S, Moriya S, Umemoto K, Watanabe K, Sasaki M, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Yamada I, Sasaki T, Sasahira N, Morimoto M.
    A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer.
    Pancreas. 2020 Feb;49(2):187-192
  3. Yasuda H, Horibe M, Sanui M, Sasaki M, Suzuki N, Sawano H, Goto T, Ikeura T, Takeda T, Oda T, Ogura Y, Miyazaki D, Kitamura K, Chiba N, Ozaki T, Yamashita T, Koinuma T, Oshima T, Yamamoto T, Hirota M, Sato M, Miyamoto K, Mine T, Misumi T, Takeda Y, Iwasaki E, Kanai T, Mayumi T.
    Etiology and mortality in severe acute pancreatitis: A multicenter study in Japan.
    Pancreatology. 2020 Apr;20(3):307-317
  4. Takahara N, Nakai Y, Saito K, Sasaki T, Suzuki Y, Inokuma A, Oyama H, Kanai S, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito T, Hamada T, Mizuno S, Kogure H, Tada M, Isayama H, Koike K.
    The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy.
    J Gastroenterol Hepatol. 2020 Oct;35(10):1828-1835
  5. Kogure H, Kawahata S, Mukai T, Doi S, Iwashita T, Ban T, Ito Y, Kawakami H, Hayashi T, Sasahira N, Kubota K, Togawa O, Kato H, Okabe Y, Matsubara S, Yagioka H, Saito T, Nakai Y, Isayama H.
    Multicenter randomized trial of endoscopic papillary large balloon dilation without sphincterotomy versus endoscopic sphincterotomy for removal of bile duct stones: MARVELOUS trial.
    Endoscopy. 2020 Sep;52(9):736-744
  6. Lin Y, Nakatochi M, Hosono Y, Ito H, Kamatani Y, Inoko A, Sakamoto H, Kinoshita F, Kobayashi Y, Ishii H, Ozaka M, Sasaki T, Matsuyama M, Sasahira N, Morimoto M, Kobayashi S, Fukushima T, Ueno M, Ohkawa S, Egawa N, Kuruma S, Mori M, Nakao H, Adachi Y, Okuda M, Osaki T, Kamiya S, Wang C, Hara K, Shimizu Y, Miyamoto T, Hayashi Y, Ebi H, Kohmoto T, Imoto I, Kasugai Y, Murakami Y, Akiyama M, Ishigaki K, Matsuda K, Hirata M, Shimada K, Okusaka T, Kawaguchi T, Takahashi M, Watanabe Y, Kuriki K, Kadota A, Okada R, Mikami H, Takezaki T, Suzuki S, Yamaji T, Iwasaki M, Sawada N, Goto A, Kinoshita K, Fuse N, Katsuoka F, Shimizu A, Nishizuka SS, Tanno K, Suzuki K, Okada Y, Horikoshi M, Yamauchi T, Kadowaki T, Yu H, Zhong J, Amundadottir LT, Doki Y, Ishii H, Eguchi H, Bogumil D, Haiman CA, Le Marchand L, Mori M, Risch H, Setiawan VW, Tsugane S, Wakai K, Yoshida T, Matsuda F, Kubo M, Kikuchi S, Matsuo K.
    Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer.
    Nat Commun. 2020 Jun 24;11(1):3175
  7. Uesato Y, Sasahira N, Ozaka M, Sasaki T, Takatsuki M, Zembutsu H.
    Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
    PLoS One. 2020 Jul 2;15(7):e0235623
  8. Fujimori M, Sato A, Jinno S, Okusaka T, Yamaguchi T, Ikeda M, Ueno M, Ozaka M, Takayama Y, Miyaji T, Majima Y, Uchitomi Y.
    Integrated communication support program for oncologists, caregivers and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomised controlled trial.
    BMJ Open. 2020 Sep 23;10(9):e036745
  9. Kobayashi N, Omae K, Horita Y, Ueno H, Mizuno N, Uesugi K, Sudo K, Ozaka M, Hayashi H, Okano N, Kamei K, Yamaguchi A, Kobayashi S, Suzuki S, Ishihara S, Uchiyama T, Todaka A, Fukutomi A.
    FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Pancreatology. 2020 Oct;20(7):1519-1525
  10. Takahari D, Shinozaki E, Wakatsuki T, Ooki A, Ozaka M, Suzuki T, Nakayama I, Osumi H, Kamiimabeppu D, Sato T, Ogura M, Suenaga M, Chin K, Yamaguchi K.
    Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research.
    Int J Clin Oncol. 2020 Oct 21;1-10
  11. Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T.
    nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
    Cancer Med. 2020 Dec;9(24):9396-9408
  12. Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, Ikezawa H, Hayata N, Nakajima R, Morizane C.
    Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
    BMC Cancer. 2020 Nov 16;20(1):1105
  13. Semba T, Sato R, Kasuga A, Suina K, Shibata T, Kohno T, Suzuki M, Saya H, Arima Y.
    Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d.
    Cancers (Basel). 2020 Dec 17;12(12):3805

2021年

（筆頭著者）

  1. Sasaki T, Ishibashi R, Yoshida S, Fujisawa T, Shinagawa H, Gon C, Nakai Y, Sasahira N, Saida Y, Isayama H.
    Comparing the mechanical properties of a self-expandable metallic stent for colorectal obstruction: a proposed measurement method of axial force using a new measurement machine.
    Dig Endosc. 2021 Jan;33(1):170-178.
  2. Sasaki T, Sasahira N.
    Direct Insertion of a Short-Type Single-Balloon Enteroscope and Using a Stent Retriever to Treat Difficult Bile Duct Stones in Surgically Altered Anatomy.
    Clin Endosc. 2021 Nov;54(6):937-938.
  3. Sasaki T, Takeda T, Yasue C, Tokura J, Ide D, Saito S, Sasahira N.
    Endoscopic removal of two duodenal stents that had migrated into the colon, using the invagination method.
    Endoscopy. 2021 Jun;53(6):E209-E210.
  4. Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, Kanai T, Saya H, Arima Y.
    Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Cancer Sci. 2021 May;112(5):1822-1838.
  5. Furukawa T, Sasaki T, Takeda T, Mie T, Kanata R, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma.
    Clin J Gastroenterol. 2021 Feb;14(1):386-390
  6. Fukuda K, Sasaki T, Sasahira N.
    Portal vein guidewire insertion: Rare complication of wire-guided cannulation during single-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography.
    Dig Endosc. 2021 Jan;33(1):e3-e4.
  7. Takeda T, Sasaki T, Fukuda K, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
    Int J Clin Oncol. 2021 Mar;26(3):543-551.
  8. Takeda T, Sasaki T, Mie T, Furukawa T, Kanata R, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    The safety and efficacy of self-expandable metallic stent placement for malignant biliary obstruction with surgically altered anatomy.
    Scand J Gastroenterol. 2021 Jan;56(1):94-102
  9. Sasaki T, Mie T, Sasahira N.
    Blind Spot of Enteral Stenting for Malignant Duodenal Obstruction due to Colon Cancer: A Rare Case of Duodenocolonic Fistula.
    Clin Endosc. 2021 May;54(3):443-444.
  10. Kanata R, Sasaki T, Matsuyama M, Ishigaki K, Yamada I, Ozaka M, Takano K, Takazawa Y, Ishizuka N, Sasahira N.
    Prospective study of EUS-guided tissue acquisition with a 20G core biopsy needle with a forward bevel for solid pancreatic mas.
    Medicine (Baltimore). 2021 Jan 15;100(2):e24193.
  11. Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
    Jpn J Clin Oncol. 2021 Apr 1;51(4):604-611.
  12. Furukawa T, Ozaka M, Takamatsu M, Takazawa Y, Inamura K, Inoue Y, Mie T, Takeda T, Kanata R, Kasuga A, Matsuyama M, Sasaki T, Takahashi Y, Sasahira N.
    Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Int J Surg Pathol. 2021 Aug;29(5):475-481.
  13. Mie T, Sasaki T, Takeda T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    A case of endoscopic ultrasound-guided hepaticogastrostomy for obstructive jaundice caused by intraductal papillary mucinous neoplasm-associated pancreatobiliary fistula.
    Clin J Gastroenterol. 2021 Jun;14(3):893-898.
  14. Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer.
    Jpn J Clin Oncol. 2021 Apr 30;51(5):728-736.
  15. Mie T, Sasaki T, Kanata R, Furukawa T, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Comparison of Endoscopic Ultrasound-Guided Tissue Acquisition Using a 20-Gauge Menghini Needle with a Lateral Forward Bevel and a 22-Gauge Franseen Needle A Single-Center Large Cohort Study.
    Clin Endosc. 2021 Sep;54(5):730-738.
  16. Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Improved prognosis of pancreatic cancer patients with peritoneal metastasis.
    Pancreatology. 2021 Aug;21(5):903-911.
  17. Takeda T, Sasaki T, Suzumori C, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
    Int J Clin Oncol. 2021 Jul;26(7):1293-1303.
  18. Yamada Y, Sasaki T, Takeda T, Mie T, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Igarashi Y, Sasahira N.
    A novel laser-cut fully-covered metal stent with anti-reflux valve in patients with malignant distal biliary obstruction refractory to conventional covered metal stent.
    J Hepatobiliary Pancreat Sci. 2021 Jul;28(7):563-571.
  19. Mie T, Sasaki T, Takeda T, Fukuda K, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
    Pancreas. 2021 Apr 1;50(4):595-601.
  20. Mie T, Sasaki T, Takeda T, Okamoto T, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
    Jpn J Clin Oncol. 2021 Aug 30;51(9):1416-1422.
  21. Furukawa T, Sasaki T, Ono Y, Kawano F, Takamatsu M, Mori C, Mie T, Yamada Y, Okamoto T, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Sasahira N.
    A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
    Clin J Gastroenterol. 2021 Oct;14(5):1571-1577.
  22. Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N.
    Chemotherapy for Biliary Tract Cancer in 2021.
    J Clin Med. 2021 Jul 14;10(14):3108.
  23. Takeda T, Sasaki T, Okamoto T, Sasahira N.
    Endoscopic Double Stenting for the Management of Combined Malignant Biliary and Duodenal Obstruction.
    J Clin Med. 2021 Jul 29;10(15):3372.
  24. Okamoto T, Sasaki T, Nishimura N, Takamatsu M, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Kasuga A, Matsuyama M, Ozaka M, Maruyama D, Sasahira N.
    Pancreatic follicular lymphoma: a report of two cases and literature review.
    Clin J Gastroenterol. 2021 Dec;14(6):1756-1765.
  25. Sasaki T, Yoshida S, Isayama H, Narita A, Yamada T, Enomoto T, Sumida Y, Kyo R, Kuwai T, Tomita M, Moroi R, Shimada M, Hirata N, Saida Y.
    Short-Term Outcomes of Colorectal Stenting Using a Low Axial Force Self-Expandable Metal Stent for Malignant Colorectal Obstruction: A Japanese Multicenter Prospective Study.
    J Clin Med. 2021 Oct 26;10(21):4936.

（共同著者）

  1. Okano N, Furuse J, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Nakai Y, Kobayashi S, Morimoto M, Hosoi H, Maeno S, Nagashima F, Ikeda M, Okusaka T.
    Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
    Oncologist. 2021 Feb;26(2):97-e201.
  2. Inoue Y, Saiura A, Oba A, Ono Y, Mise Y, Ito H, Sasaki T, Ozaka M, Sasahira N, Takahashi Y.
    Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery.
    J Hepatobiliary Pancreat Sci. 2021 Feb;28(2):143-155
  3. Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG).
    Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
    Jpn J Clin Oncol. 2021 Feb 8;51(2):235-243
  4. Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Takako NE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T.
    Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.
    J Hepatobiliary Pancreat Sci. 2021 Jan;28(1):1-25
  5. Semba T, Sato R, Kasuga A, Suina K, Shibata T, Kohno T, Suzuki M, Saya H, Arima Y.
    Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d.
    Cancers (Basel). 2020 Dec 17;12(12):3805
  6. Takahashi H, Ikeda M, Shiba S, Imaoka H, Todaka A, Shioji K, Yane K, Kojima Y, Kobayashi S, Asagi A, Ozaka M, Takada R, Nagashio Y, Horiguchi S, Kasuga A, Suzuki E, Terashima T, Ueno M, Morizane C, Furuse J
    Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens.
    Pancreas. 2021 Jan 1;50(1):77-82
  7. Ueno M, Morinaga S, Hashimoto Y, Umemoto K, Sasahira N, Saiura A, Seyama Y, Honda G, Ioka T, Takahashi H, Miyamoto A, Nakamori S, Unno M, Takadate T, Mizuno N, Shimizu Y, Ueno H, Sugiyama M, Fukutomi A, Shimizu S, Okusaka T, Furuse J.
    Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
    Pancreas. 2021 Jan 1;50(1):83-88
  8. Umemoto K, Takahashi H, Morizane C, Yamada I, Shimizu S, Shioji K, Yoshida Y, Motoya M, Mizuno N, Kojima Y, Terashima T, Uesugi K, Ueno M, Furuse J, Akimoto T, Ikeda M.
    FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
    Cancer Chemother Pharmacol. 2021 Mar;87(3):397-404
  9. Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Tsujimoto A, Nakamura I, Shirakawa H, Furukawa M, Ueno M, Morizane C, Furuse J.
    Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas.
    Pancreatology. 2021 Jun;21(4):738-745.
  10. Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T, Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J.
    A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
    Cancer Med. 2021 Mar;10(6):2088-2099.
  11. Saito T, Nakai Y, Mizuno S, Isayama H, Sasahira N, Kanai S, Noguchi K, Sato T, Ishigaki K, Hakuta R, Saito K, Hamada T, Takahara N, Kogure H, Koike K.
    Long-term outcome of endotherapy for pancreatic stones by using a dedicated pancreatic basket catheter.
    J Gastroenterol Hepatol. 2021 Sep;36(9):2424-2431.
  12. Hirano K, Itoi T, Sasahira N, Koyama H, Ihara F
    Coexisting Type 1 Autoimmune Pancreatitis and Mixed-type Intraductal Papillary Mucinous Neoplasm.
    Intern Med. 2021 Sep 1;60(17):2793-2797.
  13. Takahashi Y, Sasahira N, Sasaki T, Inoue Y, Mise Y, Sato T, Ono Y, Oba A, Saiura A, Ito H.
    The role of stent placement above the papilla (inside-stent) as a bridging therapy for perihilar biliary malignancy: an initial experience.
    Surg Today. 2021 Nov;51(11):1795-1804.
  14. Nakashima I, Horibe M, Sanui M, Sasaki M, Sawano H, Goto T, Ikeura T, Takeda T, Oda T, Yasuda H, Ogura Y, Miyazaki D, Kitamura K, Chiba N, Ozaki T, Yamashita T, Koinuma T, Oshima T, Yamamoto T, Hirota M, Moriya T, Shirai K, Izai J, Takeda K, Sekino M, Iwasaki E, Kanai T, Mayumi T.
    Impact of Enteral Nutrition Within 24 Hours Versus Between 24 and 48 Hours in Patients With Severe Acute Pancreatitis: A Multicenter Retrospective Study.
    Pancreas. 2021 Mar 1;50(3):371-377.
  15. Ishigaki K, Nakai Y, Sasahira N, Sugimori K, Kitamura K, Iwai T, Matsubara S, Shimura K, Itoi T, Ryozawa S, Ushio J, Doi S, Imazu H, Maetani I, Isayama H; Acquire Study Group.
    A Prospective Multicenter Study of EUS-guided Fine Needle Biopsy Using a 22-gauge Franseen Needle for Pancreatic Solid Lesions.
    J Gastroenterol Hepatol. 2021 Oct;36(10):2754-2761.
  16. Ueno M, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Miyakawa H, Yamashita T, Yasuda I, Takahashi H, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).
    Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
    Sci Rep. 2021 Jun 18;11(1):12885.
  17. Toshima F, Watanabe R, Inoue D, Yoneda N, Yamamoto T, Sasahira N, Sasaki T, Matsuyama M, Minehiro K, Tateishi U, Gabata T.
    CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than One Year Later: A Case-Control Study.
    AJR Am J Roentgenol. 2021 Dec;217(6):1353-1364.
  18. Ito G, Kawakami K, Aoyama T, Yokokawa T, Nakamura M, Ozaka M, Sasahira N, Hashiguchi M, Kizaki H, Hama T, Hori S.
    Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
    PLoS One. 2021 Jul 14;16(7):e0254726.
  19. Hiyoshi Y, Mukai T, Nagasaki T, Yamaguchi T, Nagayama S, Akiyoshi T, Sasaki T, Saito S, Fukunaga Y.
    Treatment outcome of laparoscopic surgery after self-expandable metallic stent insertion for obstructive colorectal cancer.
    Int J Clin Oncol. 2021 Nov;26(11):2029-2036.
  20. Lin Y, Nakatochi M, Sasahira N, Ueno M, Egawa N, Adachi Y, Kikuchi S.
    Glycoprotein 2 in health and disease: lifting the veil.
    Genes Environ. 2021 Dec 3;43(1):53.

2022年

（筆頭著者）

  1. Sasaki T, Takeda T, Sasahira N.
    Removal of a biliary self-expandable metal stent using the zipline technique for pancreatic cancer with duodenal stricture.
    Dig Endosc. 2022 Jan;34(1):e26-e27.
  2. Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; JCOG-HBPOG.
    The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
    Sci Rep. 2022 Jan 19;12(1):987.
  3. Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N.
    Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    Int J Mol Sci. 2022 Jan 21;23(3):1205.
  4. Yamada Y, Sasaki T, Takeda T, Okamoto T, Takamatsu M, Mori C, Mie T, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Igarashi Y, Sasahira N.
    A Case of Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer.
    Intern Med. 2022 Sep 15;61(18):2741-2746.
  5. Takeda T, Sasaki T, Inoue Y, Okamoto T, Mori C, Mie T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Takahashi Y, Saiura A, Sasahira N.
    Early-onset pancreatic cancer: Clinical characteristics and survival outcomes.
    Pancreatology. 2022 May;22(4):507-515.
  6. Furukawa T, Takamatsu M, Inoue Y, Okamoto T, Mie T, Yamada Y, Takeda T, Kasuga A, Matsuyama M, Sasaki T, Ozaka M, Oba A, Ito H, Ono Y, Sato T, Takahashi YU, Saiura A, Sasahira N.
    Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma.
    Anticancer Res. 2022 May;42(5):2645-2655.
  7. Sasaki T, Okamoto T, Yoshio T.
    Endoscopic removal of two intertwined esophageal stents from the stomach.
    Dig Endosc. 2022 Sep;34(6):e128-e129.
  8. Takeda T, Sasaki T, Mie T, Okamoto T, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Comparison of tube-assisted mapping biopsy with digital single-operator peroral cholangioscopy for preoperative evaluation of biliary tract cancer.
    Clin Endosc. 2022 Jul;55(4):549-557.
  9. Mie T, Sasaki T, Okamoto T, Takeda T, Mori C, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Jpn J Clin Oncol. 2022 Dec 5;52(12):1399-1407.
  10. Kasuga A, Nojima M, Okamoto T, Ishitsuka T, Yamada M, Nakagawa H, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Sasahira N.
    Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
    Intern Med. 2022 Dec 15;61(24):3641-3649.
  11. Mie T, Ozaka M, Okamoto T, Takeda T, Ushida Y, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Sasaki T, Inoue Y, Takahashi YU, Sasahira N.
    CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer.
    In Vivo. 2022 Nov-Dec;36(6):2844-2851.
  12. Yonekura C, Sasaki T, Mie T, Okamoto T, Takeda T, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Endoscopic Transluminal Stent Placement for Malignant Afferent Loop Obstruction.
    J Clin Med. 2022 Oct 27;11(21):6357.
  13. Yamada M, Okamoto T, Sasahira N.
    Troubleshooting with a drill dilator for the stent-in-stent technique in malignant hilar biliary obstruction.
    Endoscopy. 2022 Dec;55(S 01):E189-E190.
  14. Mie T, Sasaki T, Takeda T, Okamoto T, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.  
    Diagnostic Yield of Serial Pancreatic Juice Aspiration Cytologic Examination With Brush Cytology for Pancreatic Ductal Stenosis.
    Pancreas. 2022 Sep 1;51(8):995-999.
  15. Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG).
    A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
    Eur J Cancer. 2022 Dec 27;181:135-144.
  16. Okamoto T, Takeda T, Sasahira N. Endoscopic ultrasound-guided choledochoduodenostomy using a drill dilator. Endoscopy. 2022 Dec;55(S 01):E635-E636.

（共同著者）

  1. Osaki T, Lin Y, Sasahira N, Ueno M, Yonezawa H, Hojo F, Okuda M, Matsuyama M, Sasaki T, Kobayashi S, Tezuka S, Tanaka K, Dan N, Kuruma S, Egawa N, Kamiya S, Kikuchi S.
    Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers.
    Helicobacter. 2022 Feb;27(1):e12866.
  2. Yano T, Yoda Y, Nonaka S, Abe S, Kawata N, Yoshio T, Sasaki T, Tanaka S, Sasaki F, Maekita T, Kitano M, Matsumoto K, Isayama H, Ono H.
    Pivotal trial of a biodegradable stent for patients with refractory benign esophageal stricture.
    Esophagus. 2022 Jul;19(3):516-524.
  3. Takahashi Y, Sasaki T, Sasahira N, Ito H, Ishizuka N, Inoue Y, Mise Y, Sato T, Ono Y, Oba A, Saiura A.
    Safety and efficacy of inside-stent as bridging therapy for malignant hilar biliary obstruction: single-centre prospective study.
    Br J Surg. 2022 Apr 19;109(5):468-469.
  4. Ishioka M, Yoshio T, Sasaki T, Tamashiro A, Yoshizawa N, Suzuki K, Tokura J, Namikawa K, Tokai Y, Yoshimizu S, Horiuchi Y, Ishiyama A, Hirasawa T, Chin K, Ogura M, Sasahira N, Fujisaki J.
    Safety and Efficacy of Self-Expandable Metallic Stent Placement Using Low Radial Force Stent for Malignant Dysphagia after Radiotherapy.
    Digestion. 2022;103(4):261-268.
  5. Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y.
    Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
    Ann Surg Oncol. 2022 Aug;29(8):5038-5050.
  6. Suzuki T, Masugi Y, Inoue Y, Hamada T, Tanaka M, Takamatsu M, Arita J, Kato T, Kawaguchi Y, Kunita A, Nakai Y, Nakano Y, Ono Y, Sasahira N, Takeda T, Tateishi K, Uemura S, Koike K, Ushiku T, Takeuchi K, Sakamoto M, Hasegawa K, Kitago M, Takahashi Y, Fujishiro M; GTK Pancreatic Cancer Study Group in Japan.
    KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.
    Cancer Sci. 2022 Sep;113(9):3097-3109.
  7. Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, Kondo M, Cho H, Hirota S, Kagimura T, Kurokawa Y, Kitagawa Y; STAR ReGISTry Investigators.
    Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
    Gastric Cancer. 2022 Sep;25(5):956-965.
  8. Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, Ozaka M, Tsuji K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K, Imaoka H, Yamashita T, Miwa H, Nagano H, Arima S, Hayashi H, Naganuma A, Yamaguchi H, Hisano T, Umemoto K, Ishii S, Nakashima K, Suzuki R, Kitano Y, Misumi T, Furuse J, Ishii H.
    Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
    Oncologist. 2022 Oct 1;27(10):e774-e782.
  9. Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto Y, Kondo S, Morizane C, Ozaka M, Ikeda M, Furuse J, Okusaka T.
    Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial.
    Eur J Cancer. 2022 Aug 12;174:40-47.
  10. Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG).
    Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022 Oct 1;8(10):1447-1455.
  11. Ohmoto A, Hayashi N, Fukada I, Yamazaki M, Yunokawa M, Kasuga A, Shinozaki E, Ueki A, Tonooka A, Takeuchi K, Mori S, Kiyotani K, Takahashi S.
    Druggable gene alterations in Japanese patients with rare malignancy.
    Neoplasia. 2022 Nov;33:100834.
  12. Yoshida Y, Kobayashi S, Ueno M, Morizane C, Tsuji K, Maruki Y, Mori K, Watanabe K, Ohba A, Furuta M, Todaka A, Tsujimoto A, Ozaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Kojima Y, Suzuki E, Toshiyama R, Furukawa M, Naganuma A, Suzuki R, Miwa H, Ikeda M, Furuse J.
    Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
    Pancreatology. 2022 Dec;22(8):1159-1166.
  13. Takahara N, Nakai Y, Isayama H, Sasaki T, Morine Y, Watanabe K, Ueno M, Ioka T, Kanai M, Kondo S, Okano N, Koike K.
    A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer.
    Invest New Drugs. 2022 Feb;41(1):76-85.
  14. Inoue H, Aimono E, Kasuga A, Tanaka H, Iwasaki A, Saya H, Arima Y.
    Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer.
    Biomedicines. 2022 Dec 5;10(12):3133.

このページのTOPへ